Treatment of atherosclerosis in apolipoprotein E-deficient mice with 4- (3'-bromobenzoyl)-6,7-dimethoxyquinazoline (WHI-P164), a potent inhibitor of triglyceride synthesis

Journal of Cardiovascular Pharmacology

Volumn 35, Issue 2, 2000, Pages 179-188

  Trieu, Vuong N ^a   Liu, Xing Ping ^a   Chen, Chun Lin ^a   Uckun, Fatih M ^a  

^a PARKER HUGHES INSTITUTE   (United States)

Author keywords

Apolipoprotein E; Triglyceride; WHI P164

Indexed keywords

4 (3' BROMOBENZOYL) 6,7 DIMETHOXYQUINAZOLINE; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CELL STRAIN CACO 2; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SCREENING; DRUG SYNTHESIS; HYPERLIPOPROTEINEMIA TYPE 3; LIPOGENESIS; LIVER METABOLISM; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; AORTA; APOLIPOPROTEINS; ARTERIOSCLEROSIS; CACO-2 CELLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIETARY FATS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; ENZYMES; HUMANS; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; LIVER; MICE; MICE, INBRED C57BL; QUINAZOLINES; TIME FACTORS; TRIGLYCERIDES;

EID: 0033966661     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200002000-00002     Document Type: Article

References (4)

1. Schell WD, Myers JN. Regression of atherosclerosis: a review. Prog Cardiovasc Dis 1997;39:483-96.
2. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-9.
3. Report of the National Cholesterol Education Program Expert Panel. Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med 1988;148:36-69.
4. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.